Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: Results from the PLATO study

European Heart Journal

Volumn 37, Issue 16, 2016, Pages 1325-1333

  Hagström, Emil ^a,b   James, Stefan K ^a,b   Bertilsson, Maria ^b   Becker, Richard C ^c   Himmelmann, Anders ^d   Husted, Steen ^e   Katus, Hugo A ^f   Steg, Philippe Gabriel ^g,h,i,j   Storey, Robert F ^k   Siegbahn, Agneta ^a,b   Wallentin, Lars ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c UNIVERSITY OF CINCINNATI   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e HOLSTEBRO HOSPITAL   (Denmark)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g INSERM   (France)

^h BICHAT HOSPITAL   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

more..

Author keywords

Cardiovascular risk factors; GDF 15; Major bleeding; Mortality; Myocardial infarction

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; CYSTATIN C; GROWTH DIFFERENTIATION FACTOR 15; TICAGRELOR; TROPONIN T; ANTITHROMBOCYTIC AGENT; BRAIN NATRIURETIC PEPTIDE; GDF15 PROTEIN, HUMAN; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; RANDOMIZED CONTROLLED TRIAL;

ACUTE CORONARY SYNDROME; C-REACTIVE PROTEIN; GROWTH DIFFERENTIATION FACTOR 15; HEMORRHAGE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME; TROPONIN T;

EID: 84964789176     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv491     Document Type: Article

References (24)

1. Kempf T, Bjo rklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007;28: 2858-2865.
2. Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H, Wallentin L. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation 2007;116:1540-1548.
3. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007;115: 962-971.
4. Widera C, Pencina MJ, Bobadilla M, Reimann I, Guba-Quint A, Marquardt I, Bethmann K, Korf-Klingebiel M, Kempf T, Lichtinghagen R, Katus HA, Giannitsis E, Wollert KC. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) Score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem 2013; 59:1497-1505.
5. Bonaca MP, Morrow DA, Braunwald E, Cannon CP, Jiang S, Breher S, Sabatine MS, Kempf T, Wallentin L, Wollert KC. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2011;31:203-210.
6. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 2006;98:342-350.
7. Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Schmiedt W, Unsicker K, Metz J, Kinscherf R. Involvement of growth differentiation factor-15/macrophage inhibitory cytokine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Res 2004;318: 325-333.
8. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-360.
9. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;17: 581-588.
10. Heger J, Schiegnitz E, vonWaldthausen D, Anwar MM, Piper HM, Euler G. Growth differentiation factor 15 acts anti-Apoptotic and pro-hypertrophic in adult cardiomyocytes. J Cell Physiol 2010;224:120-126.
11. Lind L, Wallentin L, Kempf T, Tapken H, Quint A, Lindahl B, Olofsson S, Venge P, Larsson A, Hulthe J, Elmgren A, Wollert KC. Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J 2009;30:2346-2353.
12. Daniels LB, Clopton P, Laughlin GA, Maisel AS, Barrett-Connor E. Growthdifferentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study. Circulation 2011;123:2101-2110.
13. Rohatgi A, Patel P, Das SR, Ayers CR, Khera A, Martinez-Rumayor A, Berry JD, McGuire DK, de Lemos JA. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem 2012;58:172-182.
14. Wallentin L, Zethelius B, Berglund L, Eggers KM, Lind L, Lindahl B, Wollert KC, Siegbahn A. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS ONE 2013;8:e78797.
15. Eggers KM, Kempf T, Wallentin L, Wollert KC, Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013;59:1091-1098.
16. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE). Circulation 2014;130:1847-1858.
17. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
18. James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. Comparison of ticagrelor, the first reversible oral P2Y (12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009; 157:599-605.
19. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics 2002;58:1-12.
20. Eggers KM, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Jantzen F, Peter T, Allhoff T, Siegbahn A, Venge P, Wollert KC, Wallentin L. Growth-differentiation factor-15 for long-Term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 2010; 3:88-96.
21. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J 2009;30:1057-1065.
22. Damman P, Wallentin L, Fox KAA, Windhausen F, Hirsch A, Clayton T, Pocock SJ, Lagerqvist B, Tijssen JGP, de Winter RJ. Long-Term cardiovascular mortality after procedure-related or spontaneous myocardial infarction in patients with non-ST-segment elevation acute coronary syndrome: a collaborative analysis of individual patient data from the FRISC II, ICTUS, and RITA-3 tri. Circulation 2012;125: 568-576.
23. Hagstrom E, Eriksson N, Johansson A, Bertilsson M, Axelsson T, Barratt BJ, Becker RC, Himmelmann A, James SK, Katus HA, Siegbahn A, Steg PG, Storey RF, Syvanen A-C, Varenhorst C, Akerblom A, Wallentin L. Are there any causal relations between growth differentiation factor 15 and outcomes in patients with acute coronary syndrome?-A report from the Plato Gwas Study. Circulation 2013;128:A17372.
24. Rossaint J, Vestweber D, Zarbock A. GDF-15 prevents platelet integrin activation and thrombus formation. J Thromb Haemost 2013;11:335-344.